arterys logo

Arterys and Tempus’ Precision Merger

//
Categories

Arterys was just acquired by precision medicine AI powerhouse Tempus Labs, marking perhaps the biggest acquisition in the history of imaging AI, and highlighting the segment’s continued shift beyond traditional radiology use cases.

Arterys has become one of imaging’s AI platform and cardiac MRI 4D flow leaders, leveraging its 12 years of work and $70M in funding to build out a large team of imaging/AI experts, a solid customer base, and an attractive intellectual property portfolio (AI models, cloud viewer, and a unique multi-vendor platform).

Tempus Labs might not be a household name among Imaging Wire readers, but they’ve become a giant in the precision medicine AI space, using $1.1B in VC funding and the “largest library of clinical & molecular data” to develop a range of precision medicine and treatment discovery / development / personalization capabilities.

It appears that Arterys will continue to operate its core radiology AI business (with far more financial support), while supporting the imaging side of Tempus’s products and strategy.

This acquisition might not be as unprecedented as some think. We’ve seen imaging AI assume a central role within a number of next-generation drug discovery/development companies, including Owkin and nference (who recently acquired imaging AI startup Predible), while traditional imaging AI startups like Quibim have made pharma and life science companies a bigger part of their target market.

Of course, many will point out how this acquisition continues 2022’s AI shakeup, which brought at least five other AI acquisitions (Aidence & Quantib by RadNet; Nines by Sirona, MedoAI by Exo, Predible by nference) and two strategic pivots (MaxQ AI & Kheiron). Although these acquisitions weren’t positive signs for the AI segment, they revealed that imaging AI startups are attractive to a far more diverse range of companies than many could have imagined back in 2021 (including pharma and life sciences).

The Takeaway

Arterys just transitioned from being an independently-held leader of the (promising but challenged) diagnostic imaging AI segment to being a key part of one of the hottest companies in healthcare AI, all while managing to keep its radiology business intact. That might not be the exit that Arterys’ founders envisioned, but in many ways it’s an ideal second chapter.

Source: https://theimagingwire.com/2022/10/05/arterys-and-tempus-precision-merger/